Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | EYA3 | Q99504 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TPMT | P51580 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | TOP1 | P11387 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25779809 | 0.82 | TPMT (0.39) | ESR1CA1CA2TPMTALDH1A1 | |
| SCHEMBL28129734 | 0.82 | EYA3 (0.53) | ESR1EYA3POLBKDM4ECA12 | |
| SCHEMBL7262131 | 0.80 | TPMT (0.38) | ESR1CA1CA2MAPTTPMT | |
| SCHEMBL566608 | 0.80 | CA12 (0.64) | ESR1EYA3POLBKDM4ECA12 | |
| SCHEMBL30329647 | 0.80 | CA12 (0.64) | ESR1EYA3POLBKDM4ECA12 | |
| SCHEMBL8484882 | 0.79 | CA12 (0.62) | POLBKDM4ECA12CA1CA2 | |
| SCHEMBL30058845 | 0.78 | PKM (0.55) | ESR1EYA3POLBKDM4ECA12 | |
| SCHEMBL2964828 | 0.78 | TSHR (0.43) | POLBKDM4EMAPTTPMTALDH1A1 | |
| SCHEMBL10962857 | 0.78 | LCK (0.53) | ESR1EYA3POLBKDM4ECA12 | |
| SCHEMBL4727563 | 0.78 | TPMT (0.37) | ESR1CA1CA2TPMTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281060-B2 | Remodilins for airway remodeling and organ fibrosis | THE UNIVERSITY OF CHICAGO (US) | 2025-04-22 | — | — | US | disclosed |
| US-20240415851-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | THE UNIVERSITY OF CHICAGO (US) | 2024-12-19 | — | — | US | disclosed |
| US-20220177422-A1 | REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS | THE UNIVERSITY OF CHICAGO (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220040207-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | THE UNIVERSITY OF CHICAGO (US) | 2022-02-10 | — | — | US | disclosed |
| EP-3946301-A1 | REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS | The University of Chicago (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020206109-A1 | REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS | THE UNIVERSITY OF CHICAGO (US) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020206118-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | THE UNIVERSITY OF CHICAGO (US) | 2020-10-08 | — | — | WO | disclosed |
| US-9416317-B2 | Polymerizable liquid crystal compound, polymerizable liquid crystal composition, and optical anisotropic body | LG CHEM, LTD. (KR) | 2016-08-16 | — | — | US | disclosed |
| US-9416317-B2 | Polymerizable liquid crystal compound, polymerizable liquid crystal composition, and optical anisotropic body | LG CHEM, LTD. (KR) | 2016-08-16 | — | — | US | disclosed |
| US-20160024385-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, AND OPTICAL ANISOTROPIC BODY | LG CHEM, LTD. (KP) | 2016-01-28 | — | — | US | disclosed |
| US-20160024385-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, AND OPTICAL ANISOTROPIC BODY | LG CHEM, LTD. (KP) | 2016-01-28 | — | — | US | disclosed |
| US-9206355-B2 | Polymerizable liquid crystal compound, polymerizable liquid crystal composition, and optically anisotropic body | LG CHEM, LTD. (KR) | 2015-12-08 | — | — | US | disclosed |
| US-9206355-B2 | Polymerizable liquid crystal compound, polymerizable liquid crystal composition, and optically anisotropic body | LG CHEM, LTD. (KR) | 2015-12-08 | — | — | US | disclosed |
| US-20150115199-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, AND OPTICALLY ANISOTROPIC BODY | LG CHEM, LTD. (KR) | 2015-04-30 | — | — | US | disclosed |
| US-20150115199-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, AND OPTICALLY ANISOTROPIC BODY | LG CHEM, LTD. (KR) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220040207-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | HIF1AN, RHOXF2, HIF1A | ESR1 3612/4885EYA3 106/4885POLB 4536/4885 |
| US-20220177422-A1 | REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS | MYLK, MFAP1, FIBP | ESR1 4447/4885EYA3 1961/4885POLB 4546/4885 |
| US-12281060-B2 | Remodilins for airway remodeling and organ fibrosis | MYLK, MFAP1, FIBP | ESR1 4447/4885EYA3 1961/4885POLB 4546/4885 |
| US-20240415851-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | HIF1AN, RHOXF2, HIF1A | ESR1 3612/4885EYA3 106/4885POLB 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.